Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK).

Cao J, Meng S, Chang E, Beckwith-Fickas K, Xiong L, Cole RN, Radovick S, Wondisford FE, He L.

J Biol Chem. 2014 Jul 25;289(30):20435-46.

2.

Metformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex.

Meng S, Cao J, He Q, Xiong L, Chang E, Radovick S, Wondisford FE, He L.

J Biol Chem. 2015 Feb 6;290(6):3793-802. doi: 10.1074/jbc.M114.604421. Epub 2014 Dec 23.

PMID:
25538235
3.

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B.

J Clin Invest. 2010 Jul;120(7):2355-69. doi: 10.1172/JCI40671. Epub 2010 Jun 23.

4.

Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.

Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, Jang WG, Cho WJ, Ha J, Lee IK, Lee CH, Choi HS.

Diabetes. 2008 Feb;57(2):306-14. Epub 2007 Oct 1.

5.

AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner.

Lee JM, Seo WY, Song KH, Chanda D, Kim YD, Kim DK, Lee MW, Ryu D, Kim YH, Noh JR, Lee CH, Chiang JY, Koo SH, Choi HS.

J Biol Chem. 2010 Oct 15;285(42):32182-91. doi: 10.1074/jbc.M110.134890. Epub 2010 Aug 5.

6.

Metformin suppresses hepatic gluconeogenesis and lowers fasting blood glucose levels through reactive nitrogen species in mice.

Fujita Y, Hosokawa M, Fujimoto S, Mukai E, Abudukadier A, Obara A, Ogura M, Nakamura Y, Toyoda K, Nagashima K, Seino Y, Inagaki N.

Diabetologia. 2010 Jul;53(7):1472-81. doi: 10.1007/s00125-010-1729-5. Epub 2010 Mar 29.

PMID:
20349346
7.

Differential AMPK phosphorylation by glucagon and metformin regulates insulin signaling in human hepatic cells.

Aw DK, Sinha RA, Xie SY, Yen PM.

Biochem Biophys Res Commun. 2014 May 16;447(4):569-73. doi: 10.1016/j.bbrc.2014.04.031. Epub 2014 Apr 13.

PMID:
24735537
8.

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP.

Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ.

Nature. 2013 Feb 14;494(7436):256-60. doi: 10.1038/nature11808. Epub 2013 Jan 6.

9.

Metformin suppresses expression of the selenoprotein P gene via an AMP-activated kinase (AMPK)/FoxO3a pathway in H4IIEC3 hepatocytes.

Takayama H, Misu H, Iwama H, Chikamoto K, Saito Y, Murao K, Teraguchi A, Lan F, Kikuchi A, Saito R, Tajima N, Shirasaki T, Matsugo S, Miyamoto K, Kaneko S, Takamura T.

J Biol Chem. 2014 Jan 3;289(1):335-45. doi: 10.1074/jbc.M113.479386. Epub 2013 Nov 20.

10.
11.

Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status.

Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal E, Hue L, Viollet B, Guigas B.

Diabetologia. 2011 Dec;54(12):3101-10. doi: 10.1007/s00125-011-2311-5. Epub 2011 Sep 23.

12.

Metformin inhibits expression and secretion of PEDF in adipocyte and hepatocyte via promoting AMPK phosphorylation.

Yang S, Lv Q, Luo T, Liu L, Gao R, Chen S, Ye P, Cheng Q, Li Q.

Mediators Inflamm. 2013;2013:429207. doi: 10.1155/2013/429207. Epub 2013 Oct 31.

13.

Role of AMP-activated protein kinase in mechanism of metformin action.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE.

J Clin Invest. 2001 Oct;108(8):1167-74.

14.

AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells.

Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher P, Ruderman NB, Cohen RA.

J Biol Chem. 2004 Nov 12;279(46):47898-905. Epub 2004 Sep 14.

15.

Metformin stimulates FGF21 expression in primary hepatocytes.

Nygaard EB, Vienberg SG, Ørskov C, Hansen HS, Andersen B.

Exp Diabetes Res. 2012;2012:465282. doi: 10.1155/2012/465282. Epub 2012 Oct 15.

16.

Effects of eugenol on hepatic glucose production and AMPK signaling pathway in hepatocytes and C57BL/6J mice.

Jeong KJ, Kim do Y, Quan HY, Jo HK, Kim GW, Chung SH.

Fitoterapia. 2014 Mar;93:150-62. doi: 10.1016/j.fitote.2013.12.023. Epub 2014 Jan 11.

PMID:
24418657
17.

Metformin inhibits adenosine 5'-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons.

Chau-Van C, Gamba M, Salvi R, Gaillard RC, Pralong FP.

Endocrinology. 2007 Feb;148(2):507-11. Epub 2006 Nov 9.

PMID:
17095593
18.
19.

Convergence of IPMK and LKB1-AMPK signaling pathways on metformin action.

Bang S, Chen Y, Ahima RS, Kim SF.

Mol Endocrinol. 2014 Jul;28(7):1186-93. doi: 10.1210/me.2014-1134. Epub 2014 May 30.

20.

Energy-sensing factors coactivator peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonist.

Buler M, Aatsinki SM, Skoumal R, Komka Z, Tóth M, Kerkelä R, Georgiadi A, Kersten S, Hakkola J.

J Biol Chem. 2012 Jan 13;287(3):1847-60. doi: 10.1074/jbc.M111.302356. Epub 2011 Nov 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk